Ritu Baral
Stock Analyst at TD Cowen
(1.10)
# 3,685
Out of 4,862 analysts
36
Total ratings
42.86%
Success rate
-11.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $25.89 | +69.95% | 1 | Feb 5, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $6.70 | +34.33% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.83 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.07 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $31.33 | +148.96% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $307.99 | +20.46% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $98.73 | -0.74% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $295.57 | +31.95% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $8.27 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $36.18 | +383.69% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $21.69 | -3.16% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.32 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.73 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.11 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $22.74 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.88 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.38 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.67 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $780.63 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $25.89
Upside: +69.95%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $6.70
Upside: +34.33%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.83
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.07
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $31.33
Upside: +148.96%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $307.99
Upside: +20.46%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $98.73
Upside: -0.74%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $295.57
Upside: +31.95%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.27
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $36.18
Upside: +383.69%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $21.69
Upside: -3.16%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.32
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.73
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.11
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $22.74
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.88
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.38
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.67
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $780.63
Upside: -